Literature DB >> 29181691

Irreversible phenotypic perturbation and functional impairment of B cells during HIV-1 infection.

Jingjing Yan1, Shuye Zhang1, Jun Sun1, Jianqing Xu2, Xiaoyan Zhang3.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection can damage humoral immunity. The knowledge of B cell perturbations during chronic HIV-1 infection and their recovery after combined antiretroviral therapy (cART) is not complete yet, and thus attempts to further improve humoral immunity are impeded. In this study, an HIV-1 chronically infected cohort with similar demographics, infection history, genetic background, and HIV-1 genotype was established to probe B cell perturbations. Results showed that the B cells from this cohort were highly activated and prone to cell death, and B cell compartments were altered significantly. Notably, although cART partially reversed the hyperactivation and reduced tissue-like memory B cells, other B cell perturbations, including impaired expression of survival factor Bcl-2, costimulatory molecules, and shrunken resting memory B cells, were irreversible. Further functional characterization revealed that the influenza HAspecific antibody-secreting cells were significantly lower during HIV-1 infection, whereas the recalled antibody response to HIV-1-specific antigens was decreased after cART. Finally, CpG plus R848 treatment increased the survival of B cells and memory B cells in vitro from HIV-1-infected patients. In conclusion, this study identified irreversible B cell immune perturbations in chronic HIV-1 infections regardless of cART and proposed the potential strategy to enhance B cell functions through the improvement of cell survival.

Entities:  

Keywords:  B cell; HIV-1; antiretroviral therapy; functionality; phenotype

Mesh:

Substances:

Year:  2017        PMID: 29181691     DOI: 10.1007/s11684-017-0592-x

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  42 in total

Review 1.  Blood banking in China.

Authors:  Hua Shan; Jing-Xing Wang; Fu-Rong Ren; Yuan-Zhi Zhang; Hai-Yan Zhao; Guo-Jing Gao; Yang Ji; Paul M Ness
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

2.  Immunogenic and tolerogenic signatures in human immunodeficiency virus (HIV)-infected controllers compared with progressors and a conversion strategy of virus control.

Authors:  T Whittall; B Peters; D Rahman; C I Kingsley; R Vaughan; T Lehner
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

3.  Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7.

Authors:  Angela Malaspina; Susan Moir; Doreen G Chaitt; Catherine A Rehm; Shyam Kottilil; Judith Falloon; Anthony S Fauci
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  B-cell subset alterations and correlated factors in HIV-1 infection.

Authors:  Simone Pensieroso; Laura Galli; Silvia Nozza; Nicolas Ruffin; Antonella Castagna; Giuseppe Tambussi; Bo Hejdeman; Donatella Misciagna; Agostino Riva; Mauro Malnati; Francesca Chiodi; Gabriella Scarlatti
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

6.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

7.  Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.

Authors:  Daniel E Kaufmann; Daniel G Kavanagh; Florencia Pereyra; John J Zaunders; Elizabeth W Mackey; Toshiyuki Miura; Sarah Palmer; Mark Brockman; Almas Rathod; Alicja Piechocka-Trocha; Brett Baker; Baogong Zhu; Sylvie Le Gall; Michael T Waring; Ryan Ahern; Kristin Moss; Anthony D Kelleher; John M Coffin; Gordon J Freeman; Eric S Rosenberg; Bruce D Walker
Journal:  Nat Immunol       Date:  2007-09-30       Impact factor: 25.606

8.  Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease.

Authors:  Melanie Hart; Alan Steel; Sally A Clark; Graeme Moyle; Mark Nelson; Don C Henderson; Robert Wilson; Frances Gotch; Brian Gazzard; Peter Kelleher
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

9.  Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance.

Authors:  Manuela Fogli; Carlo Torti; Fabio Malacarne; Simona Fiorentini; Melania Albani; Ilaria Izzo; Cinzia Giagulli; Fabrizio Maggi; Giampiero Carosi; Arnaldo Caruso
Journal:  Clin Dev Immunol       Date:  2012-03-05

10.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Authors:  Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry
Journal:  Nat Immunol       Date:  2008-11-30       Impact factor: 25.606

View more
  2 in total

1.  Maternal Perinatal HIV Infection Is Associated With Increased Infectious Morbidity in HIV-exposed Uninfected Infants.

Authors:  Kathleen M Powis; Amy L Slogrove; Ibeawuchi Okorafor; Lily Millen; Roberto Posada; Jocelyn Childs; Elaine J Abrams; Rhoda S Sperling; Jennifer Jao
Journal:  Pediatr Infect Dis J       Date:  2019-05       Impact factor: 2.129

2.  The Early Antibody-Dependent Cell-Mediated Cytotoxicity Response Is Associated With Lower Viral Set Point in Individuals With Primary HIV Infection.

Authors:  Xi Chen; Meilin Lin; Shi Qian; Zining Zhang; Yajing Fu; Junjie Xu; Xiaoxu Han; Haibo Ding; Tao Dong; Hong Shang; Yongjun Jiang
Journal:  Front Immunol       Date:  2018-10-09       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.